JP2025512987A5 - - Google Patents
Info
- Publication number
- JP2025512987A5 JP2025512987A5 JP2024559383A JP2024559383A JP2025512987A5 JP 2025512987 A5 JP2025512987 A5 JP 2025512987A5 JP 2024559383 A JP2024559383 A JP 2024559383A JP 2024559383 A JP2024559383 A JP 2024559383A JP 2025512987 A5 JP2025512987 A5 JP 2025512987A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- apoa
- lipid
- formulation according
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263328210P | 2022-04-06 | 2022-04-06 | |
| US63/328,210 | 2022-04-06 | ||
| PCT/IB2023/000183 WO2023194798A1 (en) | 2022-04-06 | 2023-04-06 | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025512987A JP2025512987A (ja) | 2025-04-22 |
| JP2025512987A5 true JP2025512987A5 (cg-RX-API-DMAC7.html) | 2026-04-14 |
Family
ID=86732365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559383A Pending JP2025512987A (ja) | 2022-04-06 | 2023-04-06 | 脂質結合タンパク質に基づく複合体を使用して白血球増加、内皮機能不全、および心臓炎を処置する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250255931A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4504233A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025512987A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240171131A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119317440A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023251245A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3247588A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL316100A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024012302A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023194798A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5128318A (en) | 1987-05-20 | 1992-07-07 | The Rogosin Institute | Reconstituted HDL particles and uses thereof |
| GB8712540D0 (en) | 1987-05-28 | 1987-07-01 | Ucb Sa | Expression of human proapolipoprotein a-i |
| US5220043A (en) | 1991-03-21 | 1993-06-15 | Ohio University | Synthesis of D-erythro-sphingomyelins |
| SE9103701D0 (sv) | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
| EP0751961A1 (en) | 1994-03-22 | 1997-01-08 | Research Corporation Technologies, Inc. | Eating suppressant peptides |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| DK1290013T3 (da) | 2000-04-21 | 2006-06-26 | Amgen Inc | Apo-A1/All-peptidderivater |
| US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7144862B2 (en) | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| WO2002038609A2 (en) | 2000-11-10 | 2002-05-16 | Proteopharma Aps | Apolipoprotein conjugates |
| US7217785B2 (en) | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
| ES2304452T3 (es) | 2001-08-20 | 2008-10-16 | Csl Behring Ag | Una hdl para el tratamiento de un ictus y de otras condiciones isquemicas. |
| US7223726B2 (en) | 2002-01-14 | 2007-05-29 | The Regents Of The University Of California | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same |
| MXPA04011312A (es) | 2002-05-17 | 2005-02-14 | Esperion Therapeutics Inc | Metodo para el tratamiento de desordenes dislipidemicos. |
| US6953840B2 (en) | 2002-07-30 | 2005-10-11 | Esperion Therapeutics, Inc. | Methods of using non-human animal Apolipoprotein A-I protein |
| WO2004073684A2 (en) | 2003-02-14 | 2004-09-02 | Children's Hospital & Research Center At Oakland | Lipophilic drug delivery vehicle and methods of use thereof |
| JP5048486B2 (ja) | 2004-07-16 | 2012-10-17 | トラスティーズ オブ タフツ カレッジ | アポリポタンパク質a1の模倣物とその使用 |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| BRPI0614966A2 (pt) | 2005-08-26 | 2016-09-13 | Cerenis Therapeutics Holding S A | vetor de expressão, bactéria de ácido lático, apolipoproteína isenta de endotoxina, e, método de produção de uma apolipoproteína isenta de endotoxina |
| US8541236B2 (en) | 2006-12-08 | 2013-09-24 | University Of Washington | Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls |
| WO2008104890A2 (en) | 2007-02-28 | 2008-09-04 | Cerenis Therapeutics Holding Sa | Compositions and methods for producing apolipoprotein |
| US9173890B2 (en) | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| ES2601830T3 (es) | 2007-10-23 | 2017-02-16 | The Cleveland Clinic Foundation | Apolipoproteína A-1 resistente a oxidantes y péptidos miméticos |
| MX2011008599A (es) | 2009-02-16 | 2011-11-18 | Cerenis Therapeutics Sa | Peptidos mimeticos de la apolipoproteina a-i. |
| WO2011143362A1 (en) | 2010-05-11 | 2011-11-17 | Esperion Therapeutics, Inc. | Dimeric oxidation-resistant apolipoprotein a1 variants |
| LT2673296T (lt) | 2011-02-07 | 2019-02-25 | Cerenis Therapeutics Holding Sa | Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai |
| SG11201506456VA (en) | 2013-03-15 | 2015-09-29 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
| US9708354B2 (en) | 2013-03-15 | 2017-07-18 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
| RU2016144908A (ru) | 2014-05-02 | 2018-06-05 | Серени Терапеутикс Холдинг Са | Маркеры hdl-терапии |
| KR20230004605A (ko) * | 2020-04-16 | 2023-01-06 | 아비오닉스 파마 에스에이 | 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법 |
| AU2021254856A1 (en) * | 2020-04-16 | 2022-11-10 | Abionyx Pharma Sa | CER-001 therapy for treating kidney disease |
-
2023
- 2023-04-06 CN CN202380044954.XA patent/CN119317440A/zh active Pending
- 2023-04-06 US US18/854,185 patent/US20250255931A1/en active Pending
- 2023-04-06 EP EP23729835.1A patent/EP4504233A1/en active Pending
- 2023-04-06 AU AU2023251245A patent/AU2023251245A1/en active Pending
- 2023-04-06 CA CA3247588A patent/CA3247588A1/en active Pending
- 2023-04-06 JP JP2024559383A patent/JP2025512987A/ja active Pending
- 2023-04-06 WO PCT/IB2023/000183 patent/WO2023194798A1/en not_active Ceased
- 2023-04-06 KR KR1020247036482A patent/KR20240171131A/ko active Pending
- 2023-04-06 IL IL316100A patent/IL316100A/en unknown
-
2024
- 2024-10-03 MX MX2024012302A patent/MX2024012302A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wiswell et al. | Bronchopulmonary segmental lavage with surfaxin (KL4-surfactant) for acute respiratory distress syndrome | |
| Jat et al. | Surfactant therapy for bronchiolitis in critically ill infants | |
| Ghodrat | Lung surfactants | |
| Heptinstall et al. | Peripheral neuritis in systemic lupus erythematosus | |
| KR102397379B1 (ko) | 자가소화의 치료용의 조성물 | |
| Sozo et al. | Effects of prenatal ethanol exposure on the lungs of postnatal lambs | |
| Kattwinkel | Synthetic surfactants: the search goes on | |
| Arii et al. | Acute encephalopathy associated with nontyphoidal salmonellosis | |
| Lal et al. | Surfactant respiratory therapy using Surfaxin/sinapultide | |
| Dixon et al. | The relationship of neuropathy to the treatment of tuberculosis with isoniazid | |
| Zhou | Successful rescue of fulminant myocarditis with mechanical circulatory support and immunosuppression therapy: A case report | |
| Chhikara et al. | Glyphosate surfactant herbicide poisoning manifestations and management: a case series | |
| Saboo et al. | Chemical pneumonitis and reactive airways dysfunction syndrome after fumigation exposure to dimethanol and glutaraldehyde: a silent menace unmasked | |
| Çarlı | Oxygen-ozone autohemotherapy in sacroiliitis | |
| CN110294791B (zh) | 具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用 | |
| JP2002522507A (ja) | 疾患状態の処置 | |
| Ueno et al. | Morphological abnormalities of erythrocyte membrane in the hereditary neurological disease with chorea, areflexia and acanthocytosis: a study with freeze-fracture electron microscopy | |
| CN1264304A (zh) | 脂基免疫调节剂组合物 | |
| JP2023509520A5 (cg-RX-API-DMAC7.html) | ||
| US20250177451A1 (en) | Extracellular vesicles for therapy | |
| Davis | Physiologic implications of the autonomic aberrations in cystic fibrosis | |
| US20240408173A1 (en) | Silk fibroin-containing composition and methods of use thereof | |
| Piloni et al. | Current management strategies and the potential of inhaled GM-CSF for the treatment of autoimmune pulmonary alveolar proteinosis | |
| JP2021522263A (ja) | 肺サーファクタントおよびbpdの予防のためのステロイドを含む治療的組合せ | |
| Lakkundi et al. | Surfactant therapy and SP-D in managing COVID-19 ARDS–therapeutic role possible |